The arrival of multiple therapies for certain rare diseases is providing more freedom to select therapies matched to a patient’s needs. However, product competition also affects—and sometimes constrains—market access to those same medicines. While commercialization of rare-disease treatments can be life-changing for patients and families, a combination of high development costs and circumscribed markets means most such drugs come with high price tags that can trigger restrictive measures from health plans.
In this second piece in a two-part series, our experts examine how treatment competition in rare conditions will change payer practices, and recommend steps manufactures can take to ensure payers perceive the full value of their products.
Download the white paper.
